同仁堂国药(03613)发布中期业绩 股东应占溢利2.35亿港元 同比增加6.9%

Core Viewpoint - Tong Ren Tang Chinese Medicine (03613) reported a revenue of HKD 762 million for the first half of 2025, representing a year-on-year increase of 14.6% [1] - The company's profit attributable to shareholders was HKD 235 million, reflecting a year-on-year growth of 6.9% [1] - Basic earnings per share stood at HKD 0.28 [1] Financial Performance - Revenue reached HKD 762 million, up 14.6% compared to the previous year [1] - Shareholder profit increased to HKD 235 million, marking a 6.9% rise year-on-year [1] - Basic earnings per share recorded at HKD 0.28 [1]